SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
sgs-742 novartis
4
novartis sgs-742
4
sgs-742 gabab
4
gabab antagonist
4
antagonist developed
4
developed saegis
4
saegis license
4
license novartis
4
novartis potential
4
potential treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!